Effects of metformin on the glycemic control, lipid profile, and arterial blood pressure of type 2 diabetic patients with metabolic syndrome already on insulin

Brazilian Journal of Medical and Biological Research

Volumn 39, Issue 4, 2006, Pages 489-494

  Mourao Junior C A ^a,b,c   Sa S R ^a   Guedes, O M S ^b   Dib, S A ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF JUIZ DE FORA   (Brazil)

^c NONE   (Brazil)

Author keywords

Blood pressure; Cholesterol; Metabolic syndrome; Metformin; Triglycerides; Type 2 diabetes mellitus

Indexed keywords

CAPTOPRIL; CHOLESTEROL; GEMFIBROZIL; GLUCOSE; HEMOGLOBIN A1C; HYDROCHLOROTHIAZIDE; INSULIN; ISOPHANE INSULIN; METFORMIN; MEVINOLIN; PROPRANOLOL;

ADULT; ARTERIAL PRESSURE; BODY MASS; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES CONTROL; DIAGNOSTIC PROCEDURE; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DYSLIPIDEMIA; DYSPEPSIA; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; HYPERTENSION; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; STATISTICAL ANALYSIS; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE;

EID: 33645823641     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2006000400009     Document Type: Review

References (32)

1. Stratton IM, Adler AI, Neil HA et al. (2000). Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. British Medical Journal, 321: 405-412.
2. Krolewski AS, Laffel LM, Krolewski M et al. (1995). Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. New England Journal of Medicine, 332: 1251-1255.
3. Turner RC, Cull CA, Frighi V et al. (1999). Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. Journal of the American Medical Association, 281: 2005-2012.
4. Reaven GM (1988). Banting lecture 1988. Role of insulin resistance in human disease. Diabetes, 37: 1595-1607.
5. Gu K, Cowie CC & Harris MI (1998). Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993. Diabetes Care, 21: 1138-1145.
6. van der Kallen CJ, Voors-Pette C & de Bruin TW (2004). Abdominal obesity and expression of familial combined hyperlipidemia. Obesity Research, 12: 2054-2061.
7. Lorenzo C, Okoloise M, Williams K et al. (2003). The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. Diabetes Care, 26: 3153-3159.
8. Poirier P, Lemieux I, Mauriege P et al. (2005). Impact of waist circumference on the relationship between blood pressure and insulin: the Quebec Health Survey. Hypertension, 45: 363-367.
9. Despres JP (2003). Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes. Diabetes and Metabolism, 29:6S53-6S61.
10. Wulffele MG, Kooy A, de Zeeuw D et al. (2004). The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. Journal of Internal Medicine, 256: 1-14.
11. Jaber LA, Nowak SN & Slaughter RR (2002). Insulin-metformin combination therapy in obese patients with type 2 diabetes. Journal of Clinical Pharmacology, 42: 89-94.
12. Strowig SM, Viles-Santa ML & Raskin P (2002). Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes. Diabetes Care, 25: 1691-1698.
13. Wulffele MG, Kooy A, Lehert P et al. (2002). Combination of insulin and metformin in the treatment of type 2 diabetes. Diabetes Care, 25: 2133-2140.
14. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001). Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Journal of the American Medical Association, 285: 2486-2497.
15. Pasquali R, Gambineri A, Biscotti D et al. (2000). Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 85: 2767-2774.
16. Kirpichnikov D, McFarlane SI & Somers JR (2002). Metformin: an update. Annals of Internal Medicine, 137: 25-33.
17. DeWitt DE & Dugdale DC (2003). Using new insulin strategies in the outpatient treatment of diabetes: clinical applications. Journal of the American Medical Association, 289: 2265-2269.
18. Ginsberg H, Plutzky J & Sobel BE (1999). A review of metabolic and cardiovascular effects of oral antidiabetic agents: beyond glucose-level lowering. Journal of Cardiovascular Risk, 6: 337-346.
19. Grant PJ (1996). The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes. Diabetes Care, 19: 64-66.
20. Yki-Jarvinen H, Ryysy L, Nikkila K et al. (1999). Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Annals of Internal Medicine, 130: 389-396.
21. Robinson AC, Burke J, Robinson S et al. (1998). The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control. Diabetes Care, 21: 701-705.
22. Groop L, Widen E, Franssila-Kallunki A et al. (1989). Different effects of insulin and oral anticliabetic agents on glucose and energy metabolism in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia, 32: 599-605.
23. Rains SG, Wilson GA, Richmond W et al. (1988). The effect of glibenclamide and metformin on serum lipoproteins in type 2 diabetes. Diabetic Medicine, 5: 653-658.
24. DeFronzo RA & Goodman AM (1995). Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multi-center Metformin Study Group. New England Journal of Medicine, 333: 541-549.
25. Nagi DK & Yudkin JS (1993). Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. Diabetes Care, 16: 621-629.
26. Giugliano D, Quatraro A, Consoli G et al. (1993). Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors. European Journal of Clinical Pharmacology, 44: 107-112.
27. Landin K, Tengborn L & Smith U (1991). Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors. Journal of Internal Medicine, 229: 181-187.
28. Manrique C, Lastra G, Whaley-Connell A et al. (2005). Hypertension and the cardiometabolic syndrome. Journal of Clinical Hypertension, 7: 471-476.
29. Tuck ML, Sowers J, Dornfeld L et al. (1981). The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. New England Journal of Medicine, 304: 930-933.
30. Katakami N, Yamasaki Y, Hayaishi-Okano R et al. (2004). Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes. Diabetologia, 47: 1906-1913.
31. Schafers RF (2003). Do effects on blood pressure contribute to improved clinical outcomes with metformin? Diabetes and Metabolism, 29: 6S62-6S70.
32. Meenakumari KJ, Agarwal S, Krishna A et al. (2004). Effects of metformin treatment on luteal phase progesterone concentration in polycystic ovary syndrome. Brazilian Journal of Medical and Biological Research, 37: 1637-1644.